bladder 

16695
单词释义
n.膀胱,皮囊,气囊(如球胆)
其他怎么记补充/纠错
词根记忆bla-=blow 吹 + er 名词后缀 → 吹得鼓起来了 → 膀胱;气囊 → bl …………
词性拓展记忆 / 词形拓展记忆
原形:bladder复数:bladders
词组和短语补充/纠错
gall bladder 胆囊
swim bladder 鱼鳔
bladder cancer 膀胱癌
单词例句
The bladder is a hollow, muscular organ that stores urine.
膀胱是一个空心的肌肉器官,用于储存尿液。
She felt the urge to urinate and quickly made her way to the bathroom.
她感到需要排尿,于是迅速走向洗手间。
After drinking plenty of water, she had to visit the restroom several times to empty her bladder.
喝了很多水后,她不得不多次去厕所清空膀胱。
The doctor diagnosed him with a bladder infection and prescribed antibiotics.
医生诊断他患有膀胱感染,并开了抗生素给他。
A bladder control problem can be a symptom of an underlying medical condition.
排尿问题可能是潜在健康状况的症状。
During a physical examination, the nurse palpated the patient's bladder to check its size.
在体检中,护士触诊了病人的膀胱以检查其大小。
A bladder sling surgery is performed to treat incontinence in women.
对于女性的失禁,会进行膀胱悬吊手术。
He underwent bladder removal surgery due to bladder cancer.
由于膀胱癌,他接受了膀胱切除手术。
It's important to empty your bladder before going to bed to prevent discomfort during the night.
睡前排空膀胱很重要,以免夜间不适。
The patient complained of a burning sensation while urinating, indicating a possible bladder inflammation.
病人报告说排尿时有灼热感,可能表示膀胱发炎。
In April, China's National Medical Products Administration approved the company's anti-PD-1 antibody tislelizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer, following the therapy's initial approval in classic Hodgkin's lymphoma in December 2019.
在4月,中国国家药品监督管理局批准了该公司的抗PD-1抗体tislelizumab用于治疗局部晚期或转移性尿路上皮癌(最常见的膀胱癌)的患者,此前该疗法于2019年12月首次被批准用于经典霍奇金淋巴瘤。
P2X3 also has a prominent role in several other medical conditions associated with pain and neurogenic hypersensitivity such as chronic cough, overactive bladder and neuropathic pain.
Tislelizumab received approval from the China National Medical Products Administration last April as a treatment for patients with locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer, following the therapy's initial approval in classical Hodgkin's lymphoma by the NMPA in December 2019.
China's biotechnology company BeiGene Ltd announced on Saturday that its anti-PD-1 antibody tislelizumab, an immunotherapy, had received approval from the China National Medical Products Administration as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC), the most common type of bladder cancer, following the therapy's initial approval in classical Hodgkin's lymphoma by the NMPA in December.
未经许可,严禁转发。QQ交流群:688169419
0
近30天助记贡献排行榜
网友新增怎么记信息
最新查询次数奖励榜
0